Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
April 16 2024 - 8:15AM
Business Wire
Endeavor BioMedicines (“Endeavor”), a clinical-stage
biotechnology company developing medicines with the potential to
deliver transformational clinical benefits to patients with
life-threatening diseases, today announced the appointment of Chris
Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings
extensive experience from the life sciences industry that will be
instrumental to Endeavor's continued growth and success.
“Chris is an extremely accomplished life sciences executive with
a deep understanding of the corporate operations, development and
strategy needs of a company like Endeavor BioMedicines,” said John
Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines.
“We know that he will be yet another exceptional addition to our
leadership team and will help us ensure operational excellence as
we continue to advance our clinical programs."
Mr. Krueger has nearly 25 years of experience in the life
science industry with operational responsibility and leadership for
multiple functional areas, including business and corporate
development, legal affairs and intellectual property, accounting
and finance, human resources, alliance management and operations.
He has negotiated a broad range of equity and debt financings,
strategic partnerships, mergers and acquisitions and licensing
transactions. Mr. Krueger’s extensive industry experience includes
serving as a founder and executive officer at Ventyx Biosciences,
Oppilan Pharma, Zomagen Biosciences, Escalier Biosciences, Vimalan
Biosciences and Akarna Therapeutics (acquired by Allergan).
Previously, he also served as an executive officer at Ardea
Biosciences (acquired by AstraZeneca), Xencor, X-Ceptor
Therapeutics (acquired by Exelixis) and Aurora Biosciences
(acquired by Vertex Pharmaceuticals). Earlier in his career, he was
a corporate lawyer at Cooley LLP representing emerging technology
companies, bringing an additional depth of insight to the team.
“I’m very impressed with Endeavor BioMedicines, including their
extraordinary leadership team, groundbreaking science and pipeline
of prospective medicines,” said Mr. Krueger. “I’m thrilled to be
joining the company at such a pivotal time and look forward to
being part of the team as they strive to bring new therapies to
patients who need them.”
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company
developing medicines with the potential to deliver transformational
clinical benefits to patients with life-threatening diseases.
Endeavor’s lead candidate, ENV-101, is an inhibitor of the Hedgehog
(Hh) signaling pathway in clinical development for the treatment of
idiopathic pulmonary fibrosis (IPF) and progressive pulmonary
fibrosis (PPF). Their second candidate, ENV-501, is a HER3
antibody-drug conjugate (ADC) for the treatment of HER3-positive
solid tumors. More information is available at
www.endeavorbiomedicines.com and on LinkedIn or X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416898207/en/
Media: Andrea Cohen Sam Brown Inc. 917-209-7163
AndreaCohen@sambrown.com